Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

VBIV

VBI Vaccines Inc.

May 17 • 02:19PM ET

0.6251

Dollar change -0.0245
Percentage change -3.77	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF URTY

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.93	Insider Own	5.94%	Shs Outstand	28.68M	Perf Week	0.82%
Market Cap	17.93M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	26.98M	Perf Month	-0.73%
Income	-83.99M	PEG	-	EPS next Q	-0.32	Inst Own	9.35%	Short Float	1.38%	Perf Quarter	-3.27%
Sales	9.41M	P/S	1.91	EPS this Y	68.94%	Inst Trans	-21.79%	Short Ratio	0.86	Perf Half Y	0.50%
Book/sh	-0.22	P/B	-	EPS next Y	77.24%	ROA	-81.40%	Short Interest	0.37M	Perf Year	-78.88%
Cash/sh	0.44	P/C	1.42	EPS next 5Y	-	ROE	-419.59%	52W Range	0.45 - 3.47	Perf YTD	6.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.00%	ROI	-	52W High	-81.99%	Beta	2.00
Dividend TTM	-	Quick Ratio	0.21	Sales past 5Y	129.46%	Gross Margin	-48.50%	52W Low	38.91%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	0.34	EPS Y/Y TTM	50.24%	Oper. Margin	-505.33%	RSI (14)	51.92	Volatility	6.10% 7.06%
Employees	138	Debt/Eq	-	Sales Y/Y TTM	553.09%	Profit Margin	-892.47%	Recom	2.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	77.41%	Payout	-	Rel Volume	0.38	Prev Close	0.65
Sales Surprise	-57.43%	EPS Surprise	-3.77%	Sales Q/Q	150.31%	Earnings	May 15 AMC	Avg Volume	431.77K	Price	0.63
SMA20	3.43%	SMA50	1.87%	SMA200	-12.62%	Trades		Volume	125,193	Change	-3.77%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-22	Downgrade	Raymond James	Strong Buy → Outperform	$5 → $2
Dec-29-21	Resumed	Jefferies	Buy	$7 → $6
Feb-25-21	Initiated	Jefferies	Buy	$7
Aug-27-20	Upgrade	Raymond James	Outperform → Strong Buy	$8 → $9
Jan-16-19	Initiated	Oppenheimer	Outperform	$9
Nov-01-17	Initiated	Canaccord Genuity	Buy	$10
Oct-10-16	Initiated	Laidlaw	Buy	$6
Jul-26-16	Initiated	Ladenburg Thalmann	Buy
May-07-15	Initiated	Noble Financial	Buy	$7

May-15-24 09:54PM	VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:00PM	VBI Vaccines Reports First Quarter 2024 Financial Results (Business Wire)
Apr-16-24 01:52PM	VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) +6.90%
08:00AM	VBI Vaccines Reports Full Year 2023 Financial Results (Business Wire)
Apr-11-24 04:05PM	VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Business Wire) -5.96%
02:45PM	Loading…
Apr-09-24 02:45PM	VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Business Wire) -28.34%
Apr-03-24 08:00AM	VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma (Business Wire) +7.47%
Apr-02-24 08:00AM	VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform (Business Wire) +13.25%
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Feb-14-24 12:48PM	Strategic Licensing Agreements: Brii Bios Expansion into Chronic Disease Treatments with VBI Vaccines (Exec Edge) -12.73%
07:00AM	VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences (Business Wire)
Feb-13-24 07:04PM	Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies (PR Newswire)
Nov-20-23 08:00AM	VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting (Business Wire) +12.20%
Nov-14-23 04:05PM	VBI Vaccines Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 08:00AM	VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program (Business Wire) +21.77%
07:30AM	Loading…
Sep-27-23 07:30AM	VBI Vaccines Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern (Business Wire) +6.81%
Sep-07-23 08:00AM	VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM (Business Wire)
Sep-06-23 08:00AM	VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFN for the Treatment of Chronic Hepatitis B (Business Wire)
Aug-14-23 08:00AM	VBI Vaccines Reports Second Quarter 2023 Financial Results (Business Wire) +7.14%
Aug-03-23 06:25PM	Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-24-23 08:00AM	VBI Vaccines Announces Closing of Underwriters Partial Exercise of Option to Purchase Additional Common Shares (Business Wire)
Jul-19-23 08:00AM	VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults (Business Wire) +7.91%
Jul-13-23 07:00AM	7 Biotech Stocks to Sell in July (InvestorPlace)
Jul-06-23 09:00AM	VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering (Business Wire) -51.24%
Jul-05-23 04:12PM	VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants (Business Wire) -8.33%
04:01PM	VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties (Business Wire)
Jun-23-23 04:05PM	VBI Vaccines Announces Results of Annual General Meeting (Business Wire) -8.30%
Jun-15-23 08:00AM	VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults (Business Wire)
Jun-07-23 08:00AM	VBI Vaccines Announces Poster Presentation at EASL 2023 (Business Wire) +17.14%
Jun-04-23 09:32AM	VBI Vaccines Inc.'s (NASDAQ:VBIV) Intrinsic Value Is Potentially 30% Above Its Share Price (Simply Wall St.)
09:25AM	Loading…
May-15-23 09:25AM	VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	VBI Vaccines Reports First Quarter 2023 Financial Results (Business Wire)
May-03-23 10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
May-01-23 10:00AM	VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-25-23 08:00AM	VBI Vaccines Appoints Vaughn Himes to Board of Directors (Business Wire) -7.44%
Apr-05-23 11:42AM	VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans (Zacks) -13.34%
Apr-04-23 01:55PM	VBI Vaccines Announces Cost Cutting Measures, Reverse Stock Split (Benzinga) -53.05%
08:00AM	VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split (Business Wire)
Mar-15-23 06:37AM	VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -9.04%
Mar-13-23 09:15AM	VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:00AM	VBI Vaccines Reports Full Year 2022 Financial Results (Business Wire)
Feb-23-23 08:00AM	VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat (Business Wire)
Feb-15-23 08:00AM	VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B (Business Wire)
Jan-24-23 06:16AM	Individual investors account for 55% of VBI Vaccines Inc.'s (NASDAQ:VBIV) ownership, while private equity firms account for 25% (Simply Wall St.)
Dec-08-22 08:00AM	VBI Vaccines Announces Health Canada Approval for PreHevbrio for the Prevention of Hepatitis B in Adults (Business Wire)
Dec-06-22 09:25AM	CEPI Boosts Coronavirus X Vaccine Search With Expanded VBI Vaccines Deal (Business Wire)
Nov-22-22 08:00AM	VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting (Business Wire)
Nov-14-22 08:00AM	VBI Vaccines to Participate in Upcoming Investor Conferences (Business Wire)
Nov-11-22 08:00AM	VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting (Business Wire)
Nov-10-22 09:15AM	VBI Vaccines, Inc. (VBIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update (Business Wire)
Nov-08-22 06:25PM	Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-22 06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Oct-17-22 08:00AM	VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference (Business Wire)
Oct-13-22 11:23AM	VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study (Zacks)
Oct-12-22 10:38AM	VBI Vaccines, Agenus Ink Partnership For Combination Brain Cancer Therapy (Benzinga) +6.91%
08:00AM	VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients (GlobeNewswire)
Sep-29-22 08:00AM	VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901 (Business Wire) -6.80%
Sep-21-22 08:00AM	VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting (Business Wire)
Sep-15-22 08:30AM	VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures (Business Wire)
Sep-08-22 01:00AM	Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri® (Business Wire)
Aug-08-22 09:15AM	VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update (Business Wire)
Aug-04-22 08:25AM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-19-22 09:25AM	What Type Of Shareholders Own The Most Number of VBI Vaccines Inc. (NASDAQ:VBIV) Shares? (Simply Wall St.) +9.98%
Jul-14-22 12:30PM	Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today (Motley Fool)
Jul-12-22 08:00AM	VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer (Business Wire) +5.98%
Jun-28-22 08:00AM	VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022 (Business Wire) -6.57%
Jun-22-22 04:06PM	VBI Vaccines Announces Results of Annual General Meeting (Business Wire) +14.17%
08:00AM	VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma (Business Wire)
Jun-07-22 08:00AM	VBI Vaccines to Participate in the Jefferies Healthcare Conference (Business Wire) +8.79%
Jun-06-22 08:00AM	VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting (Business Wire)
Jun-01-22 08:00AM	VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri, a 3-Antigen Adult Hepatitis B Vaccine (Business Wire)
May-26-22 08:00AM	VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022 (Business Wire)
May-19-22 08:00AM	VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022 (Business Wire)
May-12-22 07:12AM	Is VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load? (Simply Wall St.) +7.46%
May-09-22 09:15AM	VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -12.03%
08:00AM	VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update (Business Wire)
May-05-22 05:55PM	Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.15%
May-02-22 08:00AM	VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri, a 3-Antigen Adult Hepatitis B Vaccine (Business Wire) +7.20%
Apr-28-22 08:00AM	VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting (Business Wire)
Apr-11-22 12:19PM	When Can We Expect A Profit From VBI Vaccines Inc. (NASDAQ:VBIV)? (Simply Wall St.)
Apr-05-22 12:20PM	VBI Vaccines To Start Clinical Study Of Pan-Coronavirus Vaccine Candidate This Year (Benzinga)
08:00AM	VBI Vaccines Announces New Data and Progress of VBI-2900, VBIs eVLP Coronavirus Program (Business Wire)
Mar-29-22 08:00AM	VBI Vaccines Announces PreHevbrio is Now Available in the United States for the Prevention of Hepatitis B in Adults (Business Wire) +10.13%
Mar-15-22 08:00AM	VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference (Business Wire) +10.24%
Mar-07-22 09:15AM	VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022 (Business Wire)
07:57AM	QualTek Names New Independent Board Appointees to its Board of Directors (PR Newswire)
Feb-25-22 08:30AM	VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union (Business Wire)
Feb-23-22 04:05PM	VBI Vaccines Announces PreHevbrio [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults (Business Wire) -7.86%
08:45AM	NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-09-22 12:06PM	What Type Of Shareholders Make Up VBI Vaccines Inc.'s (NASDAQ:VBIV) Share Registry? (Simply Wall St.)
Jan-26-22 08:00AM	VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference (Business Wire) -6.36%
Jan-19-22 08:04PM	Pan-COVID-19 Vaccine Could Be a Solution to End the Pandemic; Jefferies Taps 2 Stocks to Benefit (TipRanks)
Jan-05-22 08:00AM	VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio (Business Wire) -6.01%
Dec-29-21 10:53AM	These 2 Strong Buy Penny Stocks Are Poised to Take Off, Says Raymond James (TipRanks)
Dec-09-21 08:00AM	VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada (Business Wire)
Dec-07-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +17.65%
Dec-01-21 04:15PM	VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021 (Business Wire)

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILLIS STEVEN	Director	Jul 10 '23	Buy	1.65	609,090	1,004,998	1,043,292	Jul 18 09:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VBIV

VBI Vaccines Inc.

Upgrade your FINVIZ experience